Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Waldenstrom's Macroglobulinemia: early-phase trial registry
A small indexed set (6 trials) with no open enrollment listed right now.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · none currently recruiting · #2,866 of 28,707 conditions by registered trial count
Waldenstrom's Macroglobulinemia: 6 US clinical trials tracked, none currently recruiting.
Waldenstrom's Macroglobulinemia is the subject of 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 3 of these trials.
Enrollment posture brief
Registry condition waldenstroms-macroglobulinemia
OPEN 0 | RECR 0% | LATE 0 | EARLY 5 | RANK #2866 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Waldenstrom's Macroglobulinemia has no open enrollment in this registry pull (6 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Waldenstrom's Macroglobulinemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Waldenstrom's Macroglobulinemia is recruiting below its size-band peers.
0 of 6 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Waldenstrom's Macroglobulinemia research.
Dana-Farber Cancer Institute accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Waldenstrom's Macroglobulinemia trials plan to enrol fewer than 100 people.
Median target enrolment is 39 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.
-
Waldenstrom's Macroglobulinemia research is mostly interventional.
5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
6 total, page 1 of 1
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Dana-Farber Cancer Institute
NCT01177527
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
M.D. Anderson Cancer Center
NCT00492050
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TG Therapeutics
NCT01647971
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
NCT01470196
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
NCT00142129
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
X4 Pharmaceuticals
NCT04274738
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Waldenstrom's Macroglobulinemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Waldenstrom's Macroglobulinemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Waldenstrom's Macroglobulinemia page
6 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Waldenstrom's Macroglobulinemia trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Dana-Farber Cancer Institute sponsors the most Waldenstrom's Macroglobulinemia trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Waldenstrom's Macroglobulinemia condition card totals 6 registered trials; most-linked intervention Rituximab; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.